Although vasopressin infusion reduces total norepinephrine-equivalent dose requirements and may be renal and pulmonary vasculature sparing [59], there is evidence showing a pronounced activation of the vasopressin system in COVID-19 patients and that molecular complexes form between the SARS-CoV-2 spike protein, soluble angiotensin-converting enzyme-2 (ACE2), and vasopressin, facilitating cellular infection and aggravating outcome [60, 61]. Here, ACE2 is linked to COVID-19.